News for Inozyme Pharma, Inc. (INZY)

- Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease's serious cardiovascular and musculoskele

**media[581370]**

- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including

**media[561890]**

**media[548596]**

**media[546629]**

Inozyme Pharma stock hits 52-week low at $2.37 amid market challenges

- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including surv

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. ( INZY) (”œthe Company” or ”œInozyme”), a clinical-stage biopharmaceutical company develo

**media[477598]**

Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

**media[462228]**

- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing...

Inozyme Pharma (INZY) stock gains as Stifel starts coverage citing its lead drug INZ-701 as a pipeline-in-a-product for rare disorders. Read more here.

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company...

Shares of Nikola Corporation NKLA fell sharply in Monday's session after the company announced it entered into a securities purchase agreement and filed for a m...

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free

U.S. stocks traded mostly higher toward the end of trading, with the S&P index gaining around 0.5% on Wednesday.

Read Investment Analysts’ Upgrades for May 31st (AMDUF, APEMY, CGHLY, CLX, CPE, CRNLF, CTT, CVNA, DBSDY, DEO) at ETF Daily News